Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.54 |
| ▸ | PPARG | P37231 | 11/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361346 | 1.00 | PPARA (0.54) | PPARAPPARGPPARDCNR2DRD2 | |
| SCHEMBL6545379 | 1.00 | PPARA (0.54) | PPARAPPARGPPARDCNR2DRD2 | |
| SCHEMBL6359324 | 0.92 | PPARA (0.53) | PPARAPPARGPPARDCNR2LTB4R | |
| SCHEMBL6358183 | 0.92 | PPARA (0.59) | PPARAPPARGPPARDCNR2LTB4R | |
| SCHEMBL6363619 | 0.91 | PPARA (0.53) | PPARAPPARGPPARDCNR2LTB4R | |
| SCHEMBL6360237 | 0.90 | PPARA (0.52) | PPARAPPARGPPARDCNR2LTB4R | |
| SCHEMBL6356366 | 0.90 | PPARA (0.55) | PPARAPPARGPPARD | |
| SCHEMBL6359144 | 0.89 | PPARA (0.53) | PPARAPPARGPPARDCNR2 | |
| SCHEMBL6364104 | 0.86 | PPARA (0.52) | PPARAPPARGPPARDCNR2CYP2D6 | |
| SCHEMBL6363866 | 0.86 | PPARA (0.52) | PPARAPPARGPPARDCNR2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004520397-A | — | — | 2004-07-08 | — | — | JP | claimed |
| EP-1372632-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020169192-A1 | PPAR compounds | HAYWARD CHERYL M (US) | 2002-11-14 | — | — | US | claimed |
| WO-2002064130-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169192-A1 | PPAR compounds | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.